Company Overview
More
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
CEO： Harris Ph.D., Todd
Market： NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
TYRA TYRA BIOSCIENCES, INC.
7.9700.0000.00%
Close 05/25 00:00 ET
High
0.000
Open
0.000
Turnover
0
Low
0.000
Pre Close
7.970
Volume
0
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
No Data
News
Comment
TYRA BIOSCIENCES, INC.: Quarterly report
10-Q | Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA BIOSCIENCES, INC.: Events or Changes Between Quarterly Reports
8-K | Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA BIOSCIENCES, INC.: FY2021 Annual Report
10-K | Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA BIOSCIENCES, INC.: Events or Changes Between Quarterly Reports
8-K | Tyra Biosciences, Inc. (0001863127) (Filer)
Quarterly report
10-Q | Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA BIOSCIENCES, INC.: Events or Changes Between Quarterly Reports
8-K | Tyra Biosciences, Inc. (0001863127) (Filer)
TYRA BIOSCIENCES, INC.: Events or Changes Between Quarterly Reports
8-K | Tyra Biosciences, Inc. (0001863127) (Filer)
No More